AB Science SA

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

11 Jun 2025 22:59:17 By Nasdaq GlobeNewswire

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

08 Jun 2025 23:01:20 By Nasdaq GlobeNewswire

AB Science announces the settlement delivery of its latest capital increase for €1.8 million

22 May 2025 22:52:26 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a EUR 1.8 million private placement

19 May 2025 22:49:42 By Nasdaq GlobeNewswire

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

18 May 2025 22:51:54 By Nasdaq GlobeNewswire

AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib

14 May 2025 23:07:23 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2024 and provides an update on its activities

11 May 2025 23:14:35 By Nasdaq GlobeNewswire

AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting

05 May 2025 09:03:42 By Nasdaq GlobeNewswire

AB Science will publish its 2024 annual financial report on May 9, 2025

01 May 2025 01:06:22 By Nasdaq GlobeNewswire

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 Apr 2025 09:59:03 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 Apr 2025 09:02:30 By Nasdaq GlobeNewswire

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

03 Mar 2025 23:35:15 By Nasdaq GlobeNewswire

AB Science today provides an update on its masitinib platform

29 Jan 2025 10:03:14 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24 Jan 2025 09:01:01 By Nasdaq GlobeNewswire

AB Science will participate in the Biomed Forum investors conference

22 Jan 2025 09:59:47 By Nasdaq GlobeNewswire

AB Science provides a summary of the webcast held on December 16, 2024

17 Dec 2024 10:04:08 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 Dec 2024 09:06:34 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 Oct 2024 09:47:33 By Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 Oct 2024 10:28:54 By Nasdaq GlobeNewswire

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

09 Oct 2024 23:28:04 By Nasdaq GlobeNewswire